5/2/2014 8:35:18 AM
Negotiations to buy Israeli stem cell therapies developer Gamida cell have been terminated, Gamida's parent company said on Thursday. In March, Elbit Medical Technologies - which owns a 30.8 percent stake - said Gamida had received a buyout offer worth hundreds of millions of dollars from an unnamed global pharmaceutical company. Israeli media had identified the interested buyer as Swiss drugmaker Novartis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by